ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation.

J. Choi, J. Jung, S. Shin, Y. Kim, D. Han.

Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea.

Meeting: 2016 American Transplant Congress

Abstract number: D28

Keywords: Antibodies, Kidney transplantation, Rejection

Session Information

Date: Tuesday, June 14, 2016

Session Name: Poster Session D: Antibody Mediated Rejection: Session #2

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Early Vs. Late Acute Antibody Mediated Rejection Among Renal Transplant Recipients in Terms of Its Response to Rituximab Therapy-Single Center Expereince
  • Bortezomib Treatment in Antibody Mediated Rejection After Kidney Transplantation

Although several strategies for treating antibody mediated rejection (AMR) in renal transplants have been investigated, the formation of donor-specific antibodies (DSA) and ongoing AMR contribute to late graft loss. However, it remains controversial about the treatment. As a novel treatment, there is accumulating evidence that the proteasome inhibition with bortezomib can improve the renal function of the recipient with late AMR. Herein, we analyzed the outcomes of the patients with late AMR and compared bortezomib therapy (G1) and rituximab therapy (G2).

Between March 2014 and May 2015, 149 cases AMR were diagnosed by renal biopsy based on 13'th Banff classification. Among them, 12 cases received bortezomib (1.3mg/m2 I.V) therapy and 85 cases received conventional therapy using rituximab (200mg I.V). All patients treated with steroid, plasmapheresis and selective use of Intravenous immunoglobulin (200mg/kg I.V). Response to therapy was assessed by improvement in sCr, eGFR.

Baseline characteristics and the pathologic scores in biopsy were not significantly different between two groups. However, more severe acute cellular rejection(ACR) was significantly associated with AMR (p=0.042) and past treatment history of ACR or AMR was more frequent in G1 compared to G2 (ACR: 1.33±1.30 vs. 0.57±0.76, p=0.004, AMR: 1.41±1.31 vs. 0.35±0.55, p=0.017). PRA class II was higher in G1(81.67±24.83 vs. 64.05±35.37, p=0.046). After AMR treatment, there were no significant improvement in renal function at 1,2,3 and 5 months respectively, compared to the baseline. Rebiopsy rate was not significantly different, however, the interval between the treatment and rebiopsy was significantly shorter in G1 (3.92±3.34 vs. 6.67±4.28 months, p=0.043). Graft survival after rejection treatment was better in G2 compared to G1 (at 6 months, G1: 64.8% vs. G2: 91.4% and at 1 year, G1: 32.4% vs. G2: 82.1%, p=0.002).

Although this study analyzed short-term follow-up periods, the use of bortezomib as an AMR treatment may not improve the renal function in early periods. This is thought to be that we were using bortezomib as a treatment for refractory AMR. In order to access the accurate effect and establish the indication of bortezomib, large scale and long term follow-up study is needed.

CITATION INFORMATION: Choi J, Jung J, Shin S, Kim Y, Han D. The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Choi J, Jung J, Shin S, Kim Y, Han D. The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/the-early-outcomes-of-bortezomib-therapy-in-patients-with-late-antibody-mediated-rejection-in-renal-transplantation/. Accessed January 22, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Live Related Kidney Transplant Experience in Abuja, Nigeria – First Eight Cases Ever.
    • Penis Transplantation: First U.S. Experience.
    • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
    • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
    • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
    • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.